WeTrials
Active, not recruiting

A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers

What is this study?

This early-stage clinical trial is testing a new experimental medication called NXP900 in people with advanced solid tumor cancers. Researchers want to find the safest and most effective dose of this new drug for patients whose standard treatments are no longer working.

Who can participate?

Adults aged 18 and older with advanced solid tumors that can be measured on scans may be eligible. Participants must be well enough to handle daily activities and meet specific health and treatment history requirements.

What will happen?

Participants will receive the experimental study medication, NXP900, while doctors carefully monitor their health, side effects, and how their tumor responds. You will also need to agree to regular check-ups and follow safety guidelines regarding birth control.

Where and when?

The study has locations in Phoenix, Arizona; La Jolla, California; and Denver, Colorado. Please note that this study is currently active but not actively recruiting new participants at this time.

Key Points
  • 1Testing a new experimental drug named NXP900 for advanced cancers
  • 2Designed for adults whose standard treatments have stopped working
  • 3Currently active across three locations in the United States, but not actively recruiting new participants

No related links yet

Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
Advanced Solid TumorNSCLC (Non-small Cell Lung Cancer)Renal CancerMesotheliomaNon-Small Cell Squamous Lung CancerNon-small Cell Lung Adenocarcinoma

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.